

Arsenic trioxide

Section

Cytotoxic medicines
Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Asparaginase

Section

Cytotoxic medicines
Powder for injection: 10 000 IU in vial.
Parenteral > General injections > unspecified: 10000 IU in vial powder for injection

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Lymphoid leukaemia, NOS

Bendamustine

Section

Cytotoxic medicines
Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Follicular lymphoma

Bleomycin

Section

Cytotoxic medicines
Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)

Indications

Other specified malignant neoplasms of the ovary

Unspecified malignant neoplasms of ill-defined or unspecified sites

Germ cell tumour of testis

Hodgkin lymphoma

Kaposi sarcoma of unspecified primary site

Calcium folinate

Section

Cytotoxic medicines

Oral > Solid: 15 mg tablet

Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule

Oral > Solid: 15 mg tablet; 5 mg tablet; 25 mg tablet

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasm metastasis in large intestine

Malignant trophoblastic neoplasms of placenta

Burkitt lymphoma including Burkitt leukaemia

Osteosarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of rectum

Malignant neoplasms of colon

Capecitabine

Section

Cytotoxic medicines

Oral > Solid: 150 mg tablet; 500 mg tablet

Indications

Malignant neoplasms of colon

Malignant neoplasm metastasis in large intestine

Other specified malignant neoplasms of breast

Malignant neoplasms of rectum

Carboplatin

Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL

Indications

Other specified carcinomas of ovary

Other specified malignant neoplasms of bronchus or lung

Osteosarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of breast

Malignant neoplasms of nasopharynx

Retinoblastoma

Malignant neoplasms of cervix uteri

Chlorambucil

Section

Cytotoxic medicines
Oral > Solid: 2 mg tablet

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Cisplatin

Section

Cytotoxic medicines
Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL
Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection

Indications

Other specified malignant neoplasms of the ovary

Unspecified malignant neoplasms of ill-defined or unspecified sites

Osteosarcoma of bone and articular cartilage of unspecified sites

Germ cell tumour of testis

Other specified malignant neoplasms of bronchus or lung

Squamous cell carcinoma of oropharynx

Malignant neoplasms of cervix uteri

Malignant neoplasms of nasopharynx

Cyclophosphamide

Section

Cytotoxic medicines
Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection
Oral > Solid: 25 mg tablet; 50 mg tablet

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant trophoblastic neoplasms of placenta

Ewing sarcoma of bone and articular cartilage of unspecified sites

Follicular lymphoma

Other specified malignant neoplasms of breast

Lymphoid leukaemia, NOS

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Malignant neoplasms of breast

Rhabdomyosarcoma primary site

Hodgkin lymphoma

Plasma cell myeloma

Burkitt lymphoma including Burkitt leukaemia

Diffuse large B-cell lymphomas

Cytarabine

Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 100 mg in vial powder for injection

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Lymphoid leukaemia, NOS

Acute myeloid leukaemia with recurrent genetic abnormalities

Myeloid leukaemia

Dacarbazine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 100 mg in vial powder for injection

Indications

Hodgkin lymphoma

Dactinomycin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 500 µg in vial powder for injection

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant trophoblastic neoplasms of placenta

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

Daunorubicin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (hydrochloride) powder for injection

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Lymphoid leukaemia, NOS

Myeloid leukaemia

Docetaxel

Section

Cytotoxic medicines

Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL

Indications

Malignant neoplasms of prostate

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

Unspecified malignant neoplasms of ill-defined or unspecified sites

Doxorubicin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasms of breast

Hodgkin lymphoma

Other specified malignant neoplasms of breast

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of kidney, except renal pelvis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Follicular lymphoma

Osteosarcoma of bone and articular cartilage of unspecified sites

Lymphoid leukaemia, NOS

Plasma cell myeloma

Kaposi sarcoma of unspecified primary site

Diffuse large B-cell lymphomas

Etoposide

Section

Cytotoxic medicines

Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule

Oral > Solid: 100 mg capsule

Oral > Solid: 100 mg capsule; 50 mg capsule

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified malignant neoplasms of bronchus or lung

Malignant trophoblastic neoplasms of placenta

Germ cell tumour of testis

Hodgkin lymphoma

Other specified malignant neoplasms of the ovary

Burkitt lymphoma including Burkitt leukaemia

Ewing sarcoma of bone and articular cartilage of unspecified sites

Lymphoid leukaemia, NOS

Retinoblastoma

Fludarabine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection

Oral > Solid: 10 mg tablet (fludarabine phosphate)

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Fluorouracil

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule

Indications

Malignant neoplasms of breast

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of rectum

Malignant neoplasms of colon

Malignant neoplasms of nasopharynx

Gemcitabine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection

Indications

Other specified carcinomas of ovary

Other specified malignant neoplasms of bronchus or lung

Hydroxycarbamide

Section

Cytotoxic medicines

Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g

Indications

Squamous cell carcinoma of oropharynx

Chronic myeloid leukaemia, NOS

Ifosfamide

Section

Cytotoxic medicines

Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection

Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

Other specified malignant neoplasms of the ovary

Ewing sarcoma of bone and articular cartilage of unspecified sites

Germ cell tumour of testis

Osteosarcoma of bone and articular cartilage of unspecified sites

Rhabdomyosarcoma primary site

Unspecified malignant neoplasms of ill-defined or unspecified sites

Irinotecan

Section

Cytotoxic medicines

Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial

Indications

Malignant neoplasm metastasis in large intestine

Melphalan

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection

Oral > Solid: 2 mg

Indications

Plasma cell myeloma

Mercaptopurine

Section

Cytotoxic medicines
Oral > Solid: 50 mg tablet

Indications

Lymphoid leukaemia, NOS

Unspecified malignant neoplasms of ill-defined or unspecified sites

Acute myeloid leukaemia with recurrent genetic abnormalities

Methotrexate

Section

Cytotoxic medicines
Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
Oral > Solid: 2.5 mg (as sodium salt)

Indications

Malignant neoplasms of breast

Malignant trophoblastic neoplasms of placenta

Osteosarcoma of bone and articular cartilage of unspecified sites

Lymphoid leukaemia, NOS

Unspecified malignant neoplasms of ill-defined or unspecified sites

Acute myeloid leukaemia with recurrent genetic abnormalities

Oxaliplatin

Section

Cytotoxic medicines
Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial

Indications

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of colon

Paclitaxel

Section

Cytotoxic medicines
Parenteral > General injections > IV: 6 mg per mL

Indications

Other specified malignant neoplasms of the ovary

Other specified malignant neoplasms of bronchus or lung

Kaposi sarcoma of unspecified primary site

Malignant neoplasms of nasopharynx

Other specified malignant neoplasms of breast

Other specified carcinomas of ovary

Malignant neoplasms of breast

Malignant neoplasms of cervix uteri

Pegaspargase

Section

Cytotoxic medicines

Parenteral > General injections > IV: 3750 units per 5 mL in vial

Indications

Lymphoid leukaemia, NOS

Procarbazine

Section

Cytotoxic medicines

Oral > Solid: 50 mg (as hydrochloride)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Hodgkin lymphoma

Realgar-indigo naturalis formulation

Section

Cytotoxic medicines

Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Tioguanine

Section

Cytotoxic medicines

Oral > Solid: 40 mg

Indications

Lymphoid leukaemia, NOS

Vinblastine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)

Indications

Hodgkin lymphoma

Kaposi sarcoma of unspecified primary site

Germ cell tumour of testis

Other specified malignant neoplasms of the ovary

Unspecified malignant neoplasms of ill-defined or unspecified sites

Vincristine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Kaposi sarcoma of other specified primary sites

Malignant trophoblastic neoplasms of placenta

Malignant neoplasms of kidney, except renal pelvis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Follicular lymphoma

Lymphoid leukaemia, NOS

Rhabdomyosarcoma primary site

Diffuse large B-cell lymphomas

Retinoblastoma

Hodgkin lymphoma

Burkitt lymphoma including Burkitt leukaemia

Vinorelbine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial

Indications

Other specified malignant neoplasms of bronchus or lung

Other specified malignant neoplasms of breast